Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults (CAPITA)

Clinical Trial ID NCT00744263

Rank	Title	Journal	Year	PubWeight™‹?›
1	Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.	N Engl J Med	2015	5.86
2	Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.	Am J Prev Med	2013	0.98
3	Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?	Eur J Clin Microbiol Infect Dis	2014	0.93
4	Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.	PLoS One	2016	0.88
5	Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients.	ISME J	2015	0.85
6	Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.	Adv Ther	2014	0.84
7	Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?	Australas Med J	2012	0.78
8	Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).	Vaccine	2017	0.75